| Zhang, Jingdong |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
| Active, not recruiting | 3 | 408 | RoW | KN046, placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Pancreatic Ductal Adenocarcinoma | 04/24 | 08/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 12/24 | 07/25 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer |
|
|
| Recruiting | 3 | 680 | RoW | JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 03/26 | 07/28 | | |
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations |
|
|
| Recruiting | 2a | 80 | RoW | Infigratinib, BGJ398 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor | 12/22 | 12/23 | | |
|
NCT04098796: PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Anti-PD-1 antibody, XELOX | China Medical University, China | Gastric or Gastroesophageal Junction Adenocarcinoma, AFP | 09/21 | 09/21 | | |
NCT03484195: Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer |
|
|
| Recruiting | 2 | 30 | RoW | FOLFOXIRI, Irinotecan, Oxaliplatin, 5-Fluorouracil | China Medical University, China | Colonic Neoplasms, Drug Therapy | 10/21 | 10/21 | | |
NCT03484221: Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 30 | RoW | FOLFOXIRI, Irinotecan, Oxaliplatin, 5-Fluorouracil, Short-Course Radiation Therapy(5Gy*5), XELOX, Capecitabine | China Medical University, China | Rectal Neoplasms, Drug Therapy, Radiation | 10/21 | 04/22 | | |
NCT03487939: Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer |
|
|
| Recruiting | 2 | 30 | RoW | FOLFOXIRI, Irinotecan, Oxaliplatin, 5-Fluorouracil | China Medical University, China | Colorectal Neoplasms, Drug Therapy | 10/21 | 10/21 | | |
TRAP study, NCT04483219: Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma. |
|
|
| Recruiting | 2 | 53 | RoW | TKI ± anti-PD-1 antibody | China Medical University, China | MSS, pMMR, Metastatic Colorectal Adenocarcinoma | 07/22 | 07/22 | | |
NCT04006821: PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma |
|
|
| Recruiting | 2 | 30 | RoW | PD-1 antibody, Camrelizumab, Apatinib mesylate | China Medical University, China | Gastric Cancer, AFP | 08/22 | 08/22 | | |
MRG002-002, NCT04837508: A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Recruiting | 2 | 86 | RoW | MRG002 | Shanghai Miracogen Inc. | Advanced or Metastatic Biliary Tract Cancer | 12/22 | 08/23 | | |
NCT05797883: FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 30 | RoW | FOLFOX/FOLFIRI | China Medical University, China | Unresectable or Metastatic Colorectal Cancer | 12/23 | 12/24 | | |
NCT05127759: The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation |
|
|
| Active, not recruiting | 2 | 25 | RoW | HLX208, BRAF V600E inhibitor | Shanghai Henlius Biotech | Metastatic Colorectal Cancer, mCRC | 01/24 | 06/25 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. |
|
|
| Recruiting | 2 | 60 | RoW | SPH5030 | Shanghai Pharmaceuticals Holding Co., Ltd | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | 12/26 | 12/26 | | |
AK104-IIT-025, NCT06118645: Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance |
|
|
| Not yet recruiting | 2 | 40 | NA | cadonilimab combined +paclitaxel (albumin-bound) | China Medical University, China | Gastric Adenocarcinoma | 09/24 | 08/26 | | |
NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor |
|
|
| Recruiting | 2 | 50 | RoW | TT-00420 (tinengotinib) | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma Metastatic | 06/25 | 10/25 | | |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
NCT04755543: A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms |
|
|
| Recruiting | 1 | 94 | RoW | LP002, Cisplatin, Fluorouracil, OH2 oncolytic virus | Taizhou HoudeAoke Biomedical Co., Ltd. | Digestive System Neoplasms | 06/21 | 06/22 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
| Recruiting | 1 | 60 | RoW | SG1906 | Hangzhou Sumgen Biotech Co., Ltd. | Locally Advanced Unresectable or Metastatic Solid Tumors | 02/25 | 08/25 | | |
| Recruiting | 1 | 156 | RoW | ATG-022 | Antengene Biologics Limited | Advanced/Metastatic Solid Tumors | 06/26 | 06/26 | | |
| Dong, Qian |
NCT04098796: PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Anti-PD-1 antibody, XELOX | China Medical University, China | Gastric or Gastroesophageal Junction Adenocarcinoma, AFP | 09/21 | 09/21 | | |
TRAP study, NCT04483219: Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma. |
|
|
| Recruiting | 2 | 53 | RoW | TKI ± anti-PD-1 antibody | China Medical University, China | MSS, pMMR, Metastatic Colorectal Adenocarcinoma | 07/22 | 07/22 | | |
NCT04006821: PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma |
|
|
| Recruiting | 2 | 30 | RoW | PD-1 antibody, Camrelizumab, Apatinib mesylate | China Medical University, China | Gastric Cancer, AFP | 08/22 | 08/22 | | |
NCT05797883: FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 30 | RoW | FOLFOX/FOLFIRI | China Medical University, China | Unresectable or Metastatic Colorectal Cancer | 12/23 | 12/24 | | |
NCT04908046: A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors |
|
|
| Completed | 1 | 47 | RoW | HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days . | Hutchmed | Advanced Malignant Solid Tumors | 01/24 | 02/24 | | |
